Novo, Prime in outcomes-based Victoza contract

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) signed an outcomes-based contract with PBM Prime Therapeutics LLC (Eagan, Minn.) for Type II diabetes drug Victoza liraglutide under Prime's CareCentered Contract Program. Prime did not answer inquiries about the specific outcomes or thresholds for reimbursement under the contract.

Last week, Prime signed an outcomes-based contract with Biogen Inc. (NASDAQ:BIIB) for six multiple sclerosis drugs. The contract will measure members' "overall appropriate medication use" (see BioCentury Extra, Dec. 1)...